Point-of-Care Flu Test From Mesa Biotech May Head to FDA Next Year

May 23, 2016

|

Premium

NEW YORK (GenomeWeb) – Aiming for a 2017 launch of its handheld molecular testing device and influenza A/B assay, Mesa Biotech has recently made a number of strategic hires with commercialization and leadership experience.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

Passing on Trauma, Maybe

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.